BioGaia Granted New Patent in Europe
The patent is based on several published clinical studies that show Reuteri's unique ability to significantly reduce problems that occur with severe diarrhoea.
"This new patent strengthens the protection of our products in the gut health area, in particular Reuteri Drops and Reuteri Tablets which are sold in Sweden and a series of other markets around the world," says Peter Rothschild MD BioGaia AB.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.